Mirati Therapeutics, Inc.
MRTX · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $2,547,872 | $7,610,717 | $9,881,164 | $4,828,126 |
| - Cash | $235,260 | $413,083 | $1,390,106 | $415,050 |
| + Debt | $51,505 | $45,879 | $41,905 | $0 |
| Enterprise Value | $2,364,117 | $7,243,513 | $8,532,963 | $4,413,076 |
| Revenue | $12,436 | $72,092 | $13,398 | $3,335 |
| % Growth | -82.7% | 438.1% | 301.7% | – |
| Gross Profit | $11,836 | -$436,502 | -$285,951 | -$179,531 |
| % Margin | 95.2% | -605.5% | -2,134.3% | -5,383.2% |
| EBITDA | -$756,660 | -$571,400 | -$368,722 | -$221,855 |
| % Margin | -6,084.4% | -792.6% | -2,752.1% | -6,652.3% |
| Net Income | -$740,867 | -$581,784 | -$357,937 | -$213,256 |
| % Margin | -5,957.4% | -807% | -2,671.6% | -6,394.5% |
| EPS Diluted | -13.18 | -11.21 | -7.96 | -5.69 |
| % Growth | -17.6% | -40.8% | -39.9% | – |
| Operating Cash Flow | -$570,570 | -$388,800 | -$271,531 | -$147,726 |
| Capital Expenditures | -$4,851 | -$9,795 | -$4,367 | -$1,552 |
| Free Cash Flow | -$575,421 | -$398,595 | -$275,898 | -$149,278 |